Sanofi Advances Rare Disease And Immunology Pipeline With Multiple Phase 3 Wins [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Sanofi (ENXTPA:SAN) reported that its investigational therapy venglustat met all primary endpoints in a Phase 3 trial for type 3 Gaucher disease, a rare neurological condition with no approved treatments. The company plans global regulatory filings for venglustat following the Phase 3 success. Sanofi also received a positive CHMP recommendation for conditional EU approval of Rezurock in treatment-resistant chronic graft-versus-host disease. Phase 3 results for amlitelimab in atopic dermatitis advanced, adding to late-stage progress in immunology. For investors tracking big pharma, Sanofi sits at the intersection of rare diseases and immunology, two areas that attract sustained R&D interest. The latest updates around venglustat, Rezurock, and amlitelimab provide a snapshot of how the ENXTPA:SAN pipeline is being directed toward conditions where existing options are limited or highly specialized. These data points matter because they illustrate how the company is working to b
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Why OpenAI's drug royalties deal won't work [Yahoo! Finance]Yahoo! Finance
- Pfizer sets sights on R&D strategy amid modest FY25 results [Yahoo! Finance]Yahoo! Finance
- GSK Advances Respiratory And Vaccine Growth With Key RSV And Asthma Moves [Yahoo! Finance]Yahoo! Finance
- Latent TB Diagnostics Research Report 2026: Global Market Analysis and Forecasts 2025-2029 by Assay, Risk Factor, and Lab/Place with Executive and Consultant Guides [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/6/26 - Form 6-K
- 2/5/26 - Form S-8
- 1/29/26 - Form 6-K
- SNY's page on the SEC website